NGS-Based Pan-Cancer Panels

NGS-Based Pan-Cancer Panels Vela Diagnostics, a company operating in healthcare, announced the launch of its new OncoKey SL 60 and 525 Plus panels. Vela Diagnostics unveiled its new OncoKey SL 60 and 525 Plus panels. These next-generation sequencing (NGS)-based panels are designed to detect DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue samples for up to 64 samples in a single sequencing run. The following information was provided about the new products: The company offers two pan-cancer gene panels; the focused OncoKey SL 60 Plus Panel and the comprehensive OncoKey SL 525 Plus Panel. The panel detects the following biomarkers in a single assay with just 40 ng of nucleic acid: single nucleotide variants (SNVs), insertions/deletions (INDELs), copy number variants (CNVs), microsatellite instability (MSI), fusions, splice variants, oncogenic viruses and bacteria, as well as tumor mutational burden (TMB) measurement. These NGS-based panels feature a highly automated end-to-end workflow from sample to result. Results can be produced within 5 days, requiring only 2.5 hours of active work time, and provide high sample traceability from automated sample extraction through data quality control (QC). VELA Analytics can generate concise, evidence-based institutional reports for customers to support timely and informed decisions about potential treatment options. Additionally, laboratories with low sample volumes may choose to perform assays in a manual workflow. Dr. Andreas Goertz, General Manager of Vela Diagnostics' European organization, stated: "Our OncoKey 60 and 525 Plus Panels represent an exciting advance in the field of precision medicine for cancer. These panels comprise clinically relevant genes and were designed by consulting professional guidelines, compiled clinical research and cancer databases, as well as insights from key opinion leaders in the field of oncology."